Comparative Pharmacology
Head-to-head clinical analysis: HUMULIN R versus HUMULIN R PEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HUMULIN R versus HUMULIN R PEN.
HUMULIN R vs HUMULIN R PEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Human insulin is identical to endogenous insulin. It binds to insulin receptors on target cells, activates tyrosine kinase signaling, and promotes glucose uptake, glycogenesis, lipogenesis, and protein synthesis while inhibiting gluconeogenesis and glycogenolysis.
Insulin is a hormone produced by the pancreas that regulates glucose metabolism. Exogenous insulin replaces endogenous insulin, binding to insulin receptors on cell surfaces, activating tyrosine kinase activity, and promoting glucose uptake, glycogen synthesis, and lipogenesis while inhibiting gluconeogenesis and lipolysis.
Subcutaneous: 0.2-0.6 units/kg/day divided into 2-3 doses, individualized. Intravenous: Insulin infusion protocols for hyperglycemia.
Subcutaneous injection, usual starting dose 0.2 to 0.4 units/kg/day divided into two or more injections; total daily insulin requirements may range from 0.5 to 1.0 units/kg/day.
None Documented
None Documented
Terminal elimination half-life: 0.5-1 hour (intravenous); prolonged in renal impairment (up to 3-4 hours).
Intravenous: plasma half-life is ~5-10 minutes (distribution) and elimination half-life ~1.5-2 hours (reflecting clearance from peripheral compartments). Subcutaneous: prolonged due to absorption rate-limited kinetics; terminal half-life ~5-10 hours.
Primarily renal (>90% as unchanged drug after degradation), with minor biliary/fecal elimination (<10%).
Primarily renal (hepatic metabolism to inactive metabolites accounts for <20%); ~30-80% of dose excreted unchanged in urine via glomerular filtration.
Category C
Category C
Human Insulin
Human Insulin